A Randomised, Open-Label Phase 3 Trial Comparing Amrubicin Versus Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy

NCT01207011 Phase 3 COMPLETED

The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).

Details

Lead sponsor	Sumitomo Pharma Co., Ltd.
Phase	Phase 3
Status	COMPLETED
Enrolment	202
Start date	2010-10
Completion	2014-06

Conditions

• Lung Cancer

Interventions

• Amrubicin hydrocloride
• Docetaxel

Primary outcomes

• Progression free survival — 3.3 months

Countries

Japan